医学汉英翻译记忆库19(5000条)

Chinese English

如上文所概述，本发明部分地基于水溶性功能性有机试剂用于防止或减少磷酸生产工艺中生产设备之中和/或之上形成的污垢的用途。As summarized above, the present invention is based in part on the use of water-soluble functional organic reagents for use in preventing or reducing scale formed in and/or on the production equipment in the phosphoric acid production process.

在某些实施方案中，所述试剂还可与本发明所涉及领域的技术人员已知的各种聚合物掺和在一起。In certain embodiments, the reagent can also be blended with various polymers, which are known to those skilled in the art to which the invention pertains.

根据下面结合所附实施例对本发明的不同方面进行的详细描述，本发明的这些和其它的目的、特征和优点将变得显而易见。These and other objects, features and advantages of this invention will become apparent from the following detailed description of the various aspects of the invention taken in conjunction with the accompanying Examples.

吸收校正Absorption correction

由等效值的半经验校正Semi-empirical from equivalents

vii) 具有30℃到100℃的低临界溶解温度相变(LCST)的聚合物或共聚物；和vii) a polymer or copolymer having a low critical solution temperature phase transition (LCST) from 30° C to 100° C; and

viii) 包含有机酸、聚胺和糖酸的掺合物的试剂。viii) a reagent comprising a blend of an organic acid, a polyamine, and a sugar acid.

最大和最小透射Max. and min. transmission

精修方法Refinement method

对F2的全矩阵最小二乘法Full-matrix least-squares on F2数据/约束（restraint）/参数Data / restraints / parameters

v) 包含硫酸盐、磺酸或羧酸官能团的多糖；v) a polysaccharide comprising a sulfate, sulfonic acid or carboxylic acid functional group;

vi) 包含以下单元的共聚物：含有选自(i) –(iv)的官能团的第一重复单元和具有磺酸或羧酸官能团的第二重复单元；vi) a copolymer comprising a first repeating unit containing a functional group chosen from (i) – (iv) and a second repeating unit having a sulfonic acid or carboxylic acid functional group;

对F2的拟合优良度Goodness-of-fit on F2

根据前述实施方案中任一实施方案所述的方法，其中所述添加步骤发生在所述磷酸生产工艺的任何间隙管道。A method according to any one of the preceding embodiments, wherein the adding step occurs at any of the interstitial piping of the phosphoric acid production process.

根据前述实施方案中任一实施方案所述的方法，其中所述添加步骤是在单一阶段中、在多个阶段中、依序、以反向顺序、同时或以其组合执行。A method according to any one of the preceding embodiments, wherein the adding step is performed in a single stage, in multiple stages, sequentially, in reverse order, simultaneously, or in combinations thereof.

最终的R指数[I>2ζ（I）]Final R indices [I>2sigma(I)]

表2. LMT.EDSA的原子坐标（³ 104）和等效各向同性位移参数（Å2 ³ 103）.Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103)

如请求项1之化合物，其中R5係C2-C8烷基，其中该C2-C8烷基视情况经一个、两个、三个或四个独立地选自C1-C3烷氧基、胺基、C1-C3烷基胺基、二(C1-C3烷基)胺基、卤基及C3-C8环烷基之基团取代；或R5係C1-C3烷基-Y，其中Y係或，其中R6、R7及R8係氢。A compound of claim 1 wherein R5 is C2-C8alkyl, wherein the C2-C8alkyl is optionally substituted with one, two, three, or four groups independently selected from C1-C3alkoxy, amino, C1-C3alkylamino, di(C1-C3alkyl)amino, halo, and C3-C8cycloalkyl; or R5 is C1-C3alkyl-Y wherein Y is or , wherein R6, R7, and R8 are hydrogen.

如请求项2之化合物或其医药上可接受之盐，其中R5係视情况经一个、两个、三个或四个独立地选自胺基及卤基之基团取代之C2-C8烷基。A compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R5 is C2-C8alkyl optionally substituted with one, two, three, or four groups independently selected from amino and halo.

如请求项1之化合物或其医药上可接受之盐，其中：A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R1係选自氢、C2-C4烯基、C1-C3烷氧基R1 is selected from hydrogen, C2-C4alkenyl, C1-C3alkoxy

U（eq）定义为正交的Uij张量的轨迹的1/3。U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.

在含有对-Tyr +葡萄糖（25 mM）的培养基上生长的细胞中，胰岛素未能增加葡萄糖摄取。In cells grown on medium containing p-Tyr + high glucose (25 mM), insulin failed to increase glucose uptake.

LMT.EDSA的晶体学数据（图17a）：Crystallographic Data for LMT.EDSA (Figure 17a): i) 选自以下的膦酸衍生物：i) a phosphonic acid derivative chosen from:

根据实施方案10或实施方案11所述的方法，其中所述分子量为10 kDa到30 kDa。A method according to embodiment 10 or embodiment 11, wherein the molecular weight is from 10 kDa to 30 kDa.

根据前述实施方案中任一实施方案所述的方法，其中所述试剂是共聚物调配物并且其中所述第二重复单元含有选自以下的官能团：A method according to any one of the preceding embodiments, wherein the reagent is a copolymer formulation and wherein the second repeating unit contains a functional group chosen from:

苯基膦酸、膦酰基乙酸、羟乙基氨基-二(亚甲基膦酸) (HEMPA)和其混合物；phenylphosphonic acid; phosphonoacetic acid; hydroxyethylamino-di(methylene phosphonic acid) (HEMPA); and mixtures thereof;

ii) 磺酸或选自以下的相应衍生物：ii) sulfonic acid or a corresponding derivative chosen from:

角叉菜胶、海藻酸和羧基甲基纤维素。carrageenan; alginic acid; and carboxy methyl cellulose.

根据实施方案9所述的方法，其中所述羧基甲基纤维素的分子量为2 kDa到100 kDa。A method according to embodiment 9, wherein the carboxy methyl cellulose has a molecular weight of from 2 kDa to 100 kDa.

根据实施方案10所述的方法，其中所述分子量为10 kDa到75 kDa。A method according to embodiment 10, wherein the molecular weight is from 10 kDa to 75 kDa.